Loading…
MannKind Corporation is projected to rise to $4.79 by 2027, a +17% move from its current price of $4.09. MNKD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.95 | $4.09 | $4.23 | -0.03% |
| Jul 14 | $3.90 | $4.09 | $4.29 | -0.05% |
| Jul 15 | $3.86 | $4.09 | $4.33 | -0.08% |
| Jul 16 | $3.82 | $4.09 | $4.37 | -0.10% |
| Jul 17 | $3.79 | $4.08 | $4.40 | -0.13% |
| Jul 18 | $3.76 | $4.08 | $4.43 | -0.15% |
| Jul 19 | $3.74 | $4.08 | $4.46 | -0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.74 | $4.08 | $4.46 | -0.18% |
| Week 2 | $3.59 | $4.08 | $4.62 | -0.36% |
| Week 3 | $3.49 | $4.07 | $4.75 | -0.54% |
| Week 4 | $3.40 | $4.06 | $4.85 | -0.72% |
| Week 5 | $3.32 | $4.05 | $4.95 | -0.90% |
| Week 6 | $3.25 | $4.05 | $5.03 | -1.08% |
| Week 7 | $3.19 | $4.04 | $5.11 | -1.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MannKind Corporation is a healthcare company that focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Its products include Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701.
It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MannKind Corporation (MNKD) is a healthcare company focused on chronic disease care, with a portfolio spanning inhaled insulin, wearable insulin delivery, and pulmonary hypertension therapies. It operates in the mid-cap space with a market presence in the biopharmaceutical sector and a pipeline that includes MNKD-201 and MNKD-701. The company’s combination of approved products and experimental programs highlights its strategy to address serious unmet medical needs.
As of now, MNKD trades at $4.14 with a market capitalization of $1.28B and holds the 2381st rank by market cap. The long-run price outlook in the provided forecast points to a bullish trajectory, with gradual upside across years and substantial growth by 2050. These figures are estimates, intended to reflect possible future levels rather than guarantees.
A major floor 44.3% below — a decisive break under it would weaken the trend.
The nearest floor, 17.8% below — buyers have tended to step in here.
The nearest ceiling, 10.5% above — a clean break opens room to run.
A major ceiling 25.9% above — clearing it would confirm fresh momentum.
Key MNKD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MNKD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.19 | Sell | $4.17 | Sell |
| MA 10 | $4.22 | Sell | $4.15 | Sell |
| MA 20 | $4.05 | Buy | $4.03 | Buy |
| MA 50 | $3.60 | Buy | $3.73 | Buy |
| MA 100 | $3.32 | Buy | $3.76 | Buy |
| MA 200 | $4.44 | Sell | $4.09 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.98 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 17.20 | Neutral |
| Williams %R (14) | -63.24 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | 4.07 | Buy |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 36.76 | Neutral |
| TRIX (15) | 0.83 | Buy |
| Awesome (5,34) | 0.37 | Buy |
| Ultimate (7,14,28) | 47.72 | Neutral |
| Momentum (10) | 0.16 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 4.15 | Sell |
| ADX (14) | 23.16 | Buy |
| ATR (14) | 0.12 | Info |
The near-term technical picture shows bullish sentiment overall. RSI14 sits at 60, indicating room for upside without being overbought, while the price trades above the 50-day simple moving average of $3.57, suggesting positive momentum in the short term.
The price is below the 200-day moving average of $4.45, which cushions the interpretation of longer-term strength. Support is listed at $3.36 and resistance at $4.52, framing a foothold for a potential move. The 30-day range runs from $3.30 to $5.20, indicating a relatively wide short-term trading band and ongoing volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.28 | $4.09 | $5.18 | 0% | Neutral | |
| $3.73 | $4.79 | $6.55 | +17% | Neutral | |
| $3.80 | $5.06 | $7.23 | +24% | Bullish | |
| $4.66 | $6.38 | $9.43 | +56% | Bullish | |
| $6.13 | $8.62 | $13.12 | +111% | Bullish | |
| $6.10 | $8.78 | $13.71 | +115% | Bullish | |
| $6.25 | $9.20 | $14.68 | +125% | Bullish | |
| $6.80 | $10.23 | $16.65 | +150% | Bullish | |
| $6.71 | $10.30 | $17.09 | +152% | Bullish | |
| $7.57 | $11.84 | $19.97 | +189% | Bullish | |
| $10.50 | $17.95 | $32.53 | +339% | Bullish | |
| $21.23 | $42.54 | $85.41 | +940% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.28 | $4.09 | $4.84 | +0.00% |
| August 2026 | $3.29 | $3.90 | $4.78 | -4.58% |
| September 2026 | $3.33 | $4.00 | $4.96 | +2.36% |
| October 2026 | $3.44 | $4.15 | $5.21 | +3.92% |
| November 2026 | $3.37 | $4.09 | $5.19 | -1.40% |
| December 2026 | $3.32 | $4.05 | $5.18 | -0.97% |
Click any year to see its month-by-month MNKD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MNKD to range from $2.28 to $5.18 through 2026. The $4.09 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The MNKD price prediction for 2027 points to an average of $4.79 (low $3.73, high $6.55) — a potential gain of +17% on today's $4.09. Price action looks broadly range-bound.
In 2028, MNKD is projected to trade between $3.80 and $7.23, averaging $5.06 — a potential gain of +24% from today's $4.09. That is up +6% on the projected 2027 average. Buyers look set to stay in control over this stretch.
MannKind Corporation's 2029 outlook centres on $6.38, within a $4.66 to $9.43 range. That is up +26% on the projected 2028 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2030, MNKD could reach as high as $13.12, with a base case around $8.62 and support toward $6.13 — roughly +111% from $4.09. Buyers look set to stay in control over this stretch.
Expect MNKD to range from $6.10 to $13.71 through 2031. The $8.78 average target implies a +115% move from current prices. That is up +2% on the projected 2030 average. Momentum favours further upside here.
The MNKD price prediction for 2032 points to an average of $9.20 (low $6.25, high $14.68) — a potential gain of +125% on today's $4.09. Buyers look set to stay in control over this stretch.
In 2033, MNKD is projected to trade between $6.80 and $16.65, averaging $10.23 — a potential gain of +150% from today's $4.09. That is up +11% on the projected 2032 average. Momentum favours further upside here.
MannKind Corporation's 2034 outlook centres on $10.30, within a $6.71 to $17.09 range. That is up +1% on the projected 2033 average. That marks a +152% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, MNKD could reach as high as $19.97, with a base case around $11.84 and support toward $7.57 — roughly +189% from $4.09. Momentum favours further upside here.
Expect MNKD to range from $10.50 to $32.53 through 2040. The $17.95 average target implies a +339% move from current prices. That is up +52% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The MNKD price prediction for 2050 points to an average of $42.54 (low $21.23, high $85.41) — a potential gain of +940% on today's $4.09. Momentum favours further upside here.
Investing $1,000 in MNKD today (≈ 244.498778 MNKD) could be worth
$10,400.35
+$9,400.35 (+940%) by 2050 · US Dollar
Based on the average projected MNKD price of $42.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MNKDwould be worth at today's price.
$1,000 invested in MNKD on Jul 10, 2025 (≈ 263.157898 MNKD) would be worth
$1,076.32
+$76.32 (+7.6%) today · 1.08× · US Dollar
Based on a MNKD entry price of $3.8 vs. today's $4.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.52 | $904.87 | -9.5% |
| 1 month ago | $3.63 | $1,126.72 | +12.7% |
| 3 months ago | $2.57 | $1,591.44 | +59.1% |
| 6 months ago | $5.77 | $708.84 | -29.1% |
| 1 year ago | $3.8 | $1,076.32 | +7.6% |
| All time (5.0y) ago | $4.57 | $894.97 | -10.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MNKD forecast.
Our base-case forecast reaches $8.20 around 2030.
Implied market cap at $8.20: $2.53B
The multi-year forecast paints a clearly bullish path for MannKind, with the average price rising across many future years. In 2030, the average price is forecast at $8.47 with an ROI of 104.6, and in 2050 the average is $39.83 with an ROI of 862. The years 2027–2032 remain in the bullish camp, with 2027 at an average of $4.78 and 2028 at $4.98, then lifting meaningfully later in the decade.
Beyond 2035, forecasts show continued upside, with 2035 at $11.28 (ROI 172.5) and 2040 at $16.90 (ROI 308.1). The strongest long-term upside appears in 2050, where the average is $39.83 and the max reaches $80.93, reflecting an ecosystem with significant expansion potential. These are estimates and not guarantees, and actual results can differ due to market and company-specific factors.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $8.47 with a min of $5.99 and a max of $12.98, with an ROI of 104.6 and bullish sentiment.
The forecast depicts a bullish path in the later years, with the avg price rising to $39.83 by 2050 and an ROI of 862, though early years show more modest gains and these figures are not guarantees.
Yes, the forecast shows higher potential later on: in 2040 the max is $30.93 and in 2050 the max is $80.93, while the 2050 avg is $39.83, indicating the possibility of surpassing $20 in the longer horizon.
For 2027, the avg price is $4.78 with a min of $3.71 and a max of $6.57, and the forecast sentiment is Neutral with an ROI of 15.5.
Current price is $4.14 and market cap is $1.28B.
MannKind Corporation Community Discussion
0Share your MannKind Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.